Descrizione del progetto
Prevedere l’esito del trapianto di fegato
Talvolta, il trapianto di fegato è l’unica opzione per i pazienti affetti da insufficienza epatica in fase terminale causata da cirrosi, malattia indotta dall’alcol o steatosi epatica non alcolica, oppure per coloro che soffrono di cancro al fegato. Per far fronte alla limitata disponibilità di organi, i pazienti vengono sottoposti a una valutazione di idoneità e devono soddisfare specifici criteri clinici per entrare nella lista d’attesa per il trapianto. Il progetto HepatoPredict, finanziato dall’UE, ha sviluppato uno strumento predittivo che offre un migliore supporto decisionale ai medici per la selezione dei pazienti. Lo strumento combina dati molecolari e parametri clinici per calcolare l’esito prognostico del trapianto di fegato. I risultati finora ottenuti mostrano un tasso di successo dell’82 %, offrendo un potente strumento di supporto a questa procedura.
Obiettivo
Hepatocellular carcinoma (HCC) is a leading cause of cancer related mortality world-wide. The best curative treatment option is liver transplantation. The need for liver transplants for HCC by far exceeds the number of available organs, so stringent selection criteria are of paramount importance in order to ensure that the best candidates are selected for the procedure. So far, clinicians have to rely only on clinical variables to select transplant candidates for liver transplantation. The current criteria used (MILAN criteria) limits transplant to patients within specific parameters as tumour number and diameter, clearly related to disease and tumour biological behavior, but can only act as surrogate markers of tumour stage and biology. Hence, it is not possible to predict which patients outside the Milan criteria that would have a favourable prognosis. On this background, it is of outmost importance to gain access to better predictive tools that can provide decision support in selection for these patients. In response to this challenge, Ophiomics has developed a powerful predictive tool (HepatoPredict) based on molecular signature and clinical parameters, rather than only clinical variables. We can predict the good outcome of the intervention with a successful-curative rate of 82%, improving the Milan criteria one (67%). Unsuccessful liver transplantation will be avoided and, as a consequence, better survival rate and more saved lives will be achieved. Upon 5 years after the completion of the project, HepatoPredict will boost the growth of our company generating additional 15 FTEs and a ROI of 10.49. With the help of SME instrument, Ophiomics aims to complete the clinical validation and product optimization so that it can be commercialized across European markets first, and global markets later on, improving the quality of care of healthcare systems worldwide as well as the HCC patient´s quality of life.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
1600 513 Lisboa
Portogallo
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.